FDA sanctifies term "lozenge" as the only acceptable name for solid oral dosage forms to be dissolved in the mouth. Statement is part of amendment to OTC antitussive products in the Oct. 2 Federal Register. The monograph had previously used the terms "lozenge" and "compressed tablet" interchangeably. Agency is also revising its definition of lozenge, in accordance with a new U.S. Pharmacopeial definition, to claify that oral antitussive drugs with intended systemic effects may be formulated as lozenges.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.